Efficacy and outcome analysis: Combination of Endostar and chemotherapy as a neoadjuvant treatment of stage IIIA/IIIB squamous cell lung cancer

Cao,Feiyi; Ding,Sijie; Gu,Cuiping; Zhou,Yao; Hong,Wei; Jin,Ying

doi:10.3892/ol.2023.14156

Efficacy and outcome analysis: Combination of Endostar and chemotherapy as a neoadjuvant treatment of stage IIIA/IIIB squamous cell lung cancer

Authors:
- Feiyi Cao
- Sijie Ding
- Cuiping Gu
- Yao Zhou
- Wei Hong
- Ying Jin
View Affiliations

Affiliations: Department of Medical Oncology, Postgraduate Training Base Alliance of Wenzhou Medical University (Zhejiang Cancer Hospital), Hangzhou, Zhejiang 310022, P.R. China, Department of Tumor Radiotherapy and Chemotherapy, Lishui Central Hospital, Lishui, Zhejiang 323000, P.R. China, Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine, Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, P.R. China
Published online on: November 16, 2023 https://doi.org/10.3892/ol.2023.14156
Article Number: 23
Copyright: © Cao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Patients with stage IIIA/IIIB squamous non‑small cell lung cancer (SqCLC) are particularly challenging to treat with a poor 5‑year survival rate and new treatment strategies are needed. In the present study, a retrospective, single‑center study was conducted to explore the efficacy and safety of Endostar combined with chemotherapy as the neoadjuvant treatment in patients with stage IIIA/IIIB SqCLC. A total of 27 patients with locally advanced SqCLC treated with Endostar combined with chemotherapy as neoadjuvant therapy from January 1, 2017 to December 31, 2019 at the Zhejiang Cancer Hospital (Hangzhou, China) were included. Short‑term efficacy, rate of surgical resection, long‑term outcome and adverse events were analyzed. After treatment with Endostar combined with chemotherapy, 37% of the patients underwent surgery and the radical resection rate was 90%. The objective response rate was 63% for the total population and 80% for patients who received surgery. Of note, 100% of the patients achieved disease control after treatment with Endostar combined with chemotherapy. In patients who underwent surgical resection, postoperative pathology showed that 100% of the patients achieved pathological downstaging. Furthermore, 1 (10%) patient showed a pathological complete response after surgery. The median progression‑free survival was 13.5 months and overall survival was 27.9 months for the total cohort. The most common adverse events (AEs) were anemia (69.4% of patients), followed by hypertension (29.6% of patients). Most of the AEs were grade 1‑2 and only 4 patients (14.8%) developed grade 3‑4 AEs. Endostar combined with chemotherapy was well‑tolerated and showed promising efficacy in patients with stage IIIA/IIIB SqCLC. Further prospective studies are warranted to explore its value as a neoadjuvant therapy.

View Figures

View References

1	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar : PubMed/NCBI
2	Nicholson AG, Tsao MS, Beasley MB, Borczuk AC, Brambilla E, Cooper WA, Dacic S, Jain D, Kerr KM, Lantuejoul S, et al: The 2021 WHO classification of lung tumors: Impact of advances since 2015. J Thorac Oncol. 17:362–387. 2022. View Article : Google Scholar : PubMed/NCBI
3	Feng SH and Yang ST: The new 8th TNM staging system of lung cancer and its potential imaging interpretation pitfalls and limitations with CT image demonstrations. Diagn Interv Radiol. 25:270–279. 2019. View Article : Google Scholar : PubMed/NCBI
4	Blumenthal GM, Bunn PA Jr, Chaft JE, McCoach CE, Perez EA, Scagliotti GV, Carbone DP, Aerts HJWL, Aisner DL, Bergh J, et al: Current status and future perspectives on neoadjuvant therapy in lung cancer. J Thorac Oncol. 13:1818–1831. 2018. View Article : Google Scholar : PubMed/NCBI
5	Burdett S, Stewart L, Auperin A and Pignon JP: Chemotherapy in non-small-cell lung cancer: An update of an individual patient data meta-analysis. J Clin Oncol. 23:924–925; author reply 925–926. 2005. View Article : Google Scholar : PubMed/NCBI
6	Duma N, Santana-Davila R and Molina JR: Non-Small cell lung cancer: Epidemiology, screening, diagnosis, and treatment. Mayo Clin Proc. 94:1623–1640. 2019. View Article : Google Scholar : PubMed/NCBI
7	Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, et al: Pembrolizumab versus Chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 375:1823–1833. 2016. View Article : Google Scholar : PubMed/NCBI
8	Forde PM, Chaft JE, Smith KN, Anagnostou V, Cottrell TR, Hellmann MD, Zahurak M, Yang SC, Jones DR, Broderick S, et al: Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med. 378:1976–1986. 2018. View Article : Google Scholar : PubMed/NCBI
9	Alshangiti A, Chandhoke G and Ellis PM: Antiangiogenic therapies in non-small-cell lung cancer. Curr Oncol. 25 (Suppl 1):S45–S58. 2018. View Article : Google Scholar : PubMed/NCBI
10	Rapisarda A and Melillo G: Role of the VEGF/VEGFR axis in cancer biology and therapy. Adv Cancer Res. 114:237–267. 2012. View Article : Google Scholar : PubMed/NCBI
11	Feng L, Wang Z, Jing L, Zhou Z, Shi S, Deng R, Liu Y and Meng Q: Recombinant human endostatin combined with chemotherapy for advanced squamous cell lung cancer: A meta-analysis. World J Surg Oncol. 19:642021. View Article : Google Scholar : PubMed/NCBI
12	Detterbeck FC, Boffa DJ, Kim AW and Tanoue LT: The eighth edition lung cancer stage classification. Chest. 151:193–203. 2017. View Article : Google Scholar : PubMed/NCBI
13	Schwartz LH, Litiere S, de Vries E, Ford R, Gwyther S, Mandrekar S, Shankar L, Bogaerts J, Chen A, Dancey J, et al: RECIST 1.1-Update and clarification: From the RECIST committee. Eur J Cancer. 62:132–137. 2016. View Article : Google Scholar : PubMed/NCBI
14	Freites-Martinez A, Santana N, Arias-Santiago S and Viera A: Using the common terminology criteria for adverse events (CTCAE-Version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermosifiliogr (Engl Ed). 112:90–92. 2021.(In English, Spanish). View Article : Google Scholar : PubMed/NCBI
15	Roth JA, Fossella F, Komaki R, Ryan MB, Putnam JB Jr, Lee JS, Dhingra H, De Caro L, Chasen M, McGavran M, et al: A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst. 86:673–680. 1994. View Article : Google Scholar : PubMed/NCBI
16	Rosell R, Gómez-Codina J, Camps C, Javier Sánchez J, Maestre J, Padilla J, Cantó A, Abad A and Roig J: Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: A 7-year assessment of a randomized controlled trial. Lung Cancer. 26:7–14. 1999. View Article : Google Scholar : PubMed/NCBI
17	Nagai K, Tsuchiya R, Mori T, Tada H, Ichinose Y, Koike T and Kato H; Lung Cancer Surgical Study Group of the Japan Clinical Oncology Group, : A randomized trial comparing induction chemotherapy followed by surgery with surgery alone for patients with stage IIIA N2 non-small cell lung cancer (JCOG 9209). J Thorac Cardiovasc Surg. 125:254–260. 2003. View Article : Google Scholar : PubMed/NCBI
18	Mattson KV, Abratt RP, ten Velde G and Krofta K: Docetaxel as neoadjuvant therapy for radically treatable stage III non-small-cell lung cancer: A multinational randomised phase III study. Ann Oncol. 14:116–122. 2003. View Article : Google Scholar : PubMed/NCBI
19	Uprety D, Mandrekar SJ, Wigle D, Roden AC and Adjei AA: Neoadjuvant immunotherapy for NSCLC: Current concepts and future approaches. J Thorac Oncol. 15:1281–1297. 2020. View Article : Google Scholar : PubMed/NCBI
20	Zhong WZ, Chen KN, Chen C, Gu CD, Wang J, Yang XN, Mao WM, Wang Q, Qiao GB, Cheng Y, et al: Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-Mutant non-small-cell lung cancer (EMERGING-CTONG 1103): A Randomized phase II study. J Clin Oncol. 37:2235–2245. 2019. View Article : Google Scholar : PubMed/NCBI
21	Kang J, Zhang C and Zhong WZ: Neoadjuvant immunotherapy for non-small cell lung cancer: State of the art. Cancer Commun (Lond). 41:287–302. 2021. View Article : Google Scholar : PubMed/NCBI
22	Ling Y, Yang Y, Lu N, You QD, Wang S, Gao Y, Chen Y and Guo QL: Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells. Biochem Biophys Res Commun. 361:79–84. 2007. View Article : Google Scholar : PubMed/NCBI
23	Zhai Y, Ma H, Hui Z, Zhao L, Li D, Liang J, Wang X, Xu L, Chen B, Tang Y, et al: HELPER study: A phase II trial of continuous infusion of endostar combined with concurrent etoposide plus cisplatin and radiotherapy for treatment of unresectable stage III non-small-cell lung cancer. Radiother Oncol. 131:27–34. 2019. View Article : Google Scholar : PubMed/NCBI
24	An J and Lv W: Endostar (rh-endostatin) versus placebo in combination with vinorelbine plus cisplatin chemotherapy regimen in treatment of advanced non-small cell lung cancer: A meta-analysis. Thoracic Cancer. 9:606–612. 2018. View Article : Google Scholar : PubMed/NCBI
25	Bao Y, Peng F, Zhou QC, Yu ZH, Li JC, Cheng ZB, Chen L, Hu X, Chen YY, Wang J, et al: Phase II trial of recombinant human endostatin in combination with concurrent chemoradiotherapy in patients with stage III non-small-cell lung cancer. Radiother Oncol. 114:161–166. 2015. View Article : Google Scholar : PubMed/NCBI
26	Rong B, Yang S, Li W, Zhang W and Ming Z: Systematic review and meta-analysis of Endostar (rh-endostatin) combined with chemotherapy versus chemotherapy alone for treating advanced non-small cell lung cancer. World J Surg Oncol. 10:1702012. View Article : Google Scholar : PubMed/NCBI